Dr. Whirl-Carrillo is the Director of the Pharmacogenomics Knowledgebase (PharmGKB) at Stanford University. She leads the PharmGKB team and is responsible for the development of new content, projects and features. Additionally, she holds leadership roles in multiple NIH-funded PGx projects including the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the Pharmacogenomics Clinical Annotation Tool (PharmCAT). For the past 20 years, she has led pharmacogenomics (PGx) research, focusing on its application to personalized medicine and personal genomics.
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.